Howson landed in Hong Kong with 14 new products, which heavyweights will hit in 2019?

On June 14th, Hansen Pharmaceuticals, known as the "biggest pharmaceutical IPO of the year", successfully landed in Hong Kong with a maximum offering price of HK$14.26 per share, with an estimated total capital raising of HK$7.86 billion, opening the day at HK$163,000 and with a market capitalisation of HK$102.5 billion as of 12 noon. Data show that as of June 13, 2019, the Hong Kong stock market worth more than 100 billion drug companies only the drug Mingkang, as the industry's high-profile Henson Pharmaceuticals, did not let everyone down.
Hong Kong-share pharmaceutical companies with a market capitalisation of TOP10, followed by anotherbillion (data dated June 13, 2019 close)data show that as of the close of Trading on June 13, 2019, the only Hong Kong pharmaceutical companies with a market capitalisation of more than HK$100 billion was Mingkangde, followed by Pharmaceutical Ming Bio with more than HK$90 billion. On June 14, Hansen Pharmaceuticals successfully landed in Hong Kong, with a market capitalisation of over HK$100 billion as of 12 noon.Since the first Hong Kong share prospectus was filed in September 2018, Henson Pharmaceuticals has been in a difficult position, updating the prospectus again on April 11, 2019, referring to the introduction of a new investor Boyu Fund on January 25, 2019, with a strategic financing of $248 million, with a valuation of HK$65 billion at the time. At the time, industry insiders estimated that the market-traded Henson Pharmaceuticals is expected to move into the market value of hundreds of billions of dollars, and now it seems that God's prophecy with the strong.14 new products on the road, 2019 is expected to be approved for the heavyweights?Table 2: Products approved by Howson Pharmaceuticals from 2018 to date(MED China Drug Review Database 2.0)According to Mienet data, so far in 2018, Howson Pharmaceuticals has approved 10 products, of which 1 new drug is polyglycolosena peptide injections for adults with type 2 diabetes. Among the five approved generic drugs, the acetate priscillas, Allison tan tablets, Viglitin tablets, apixaban tablets were approved according to the new classification and approved for consistent evaluation, in addition to the approved production of injectable micafen net sodium;Table 3: Howson Pharmaceuticals is currently reviewing the approval of products(MED China Drug Review Database 2.0)Howson Pharmaceuticals is currently reviewing the approval of 14 products, including two categories of 1 The new drug methadone tablets, methafulphate fluoromatinide tablets, a new class 2.2 drug O nitrogen flat oral instant film, a class 3 generic drug injection with fusapidamine, and 10 4 classes of generic drugs.Among the above-mentioned generic drugs, injection with fusapitan double glutaquine domestic no enterprises approved and no imported products, Malay acid afatini tablets, ingler net tablets, cider acid schoini capsules, hydrochloric acid erotinie tablets, palifier ketone tablets, kaglile net tablets and lynamine tablets are expected to impact the domestic first imitation.Injection consistency evaluation is difficult to move forward, 6 products impact the first reviewso far, through or as if through the consistency evaluation of only 10 injections,
and tablets as many as 96, which can be seen in the difficult. However, domestic pharmaceutical companies do not flinch, have prepared for war, currently in the review and approval of injection consistency evaluation supplementary applications involving the number of products up to 91.Table 4: Howson Pharmaceuticals is reviewing and reviewing the approval of the consistency evaluation application(MED China Drug Review Database 2.0) Howson Pharmaceuticals is currently in the review and approval of the injection consistency evaluation supplementary application involving 7 products, in addition to injection with Pometronate ii sodium has been evaluated enterprises, the remaining 6 products have the opportunity to become the first to be evaluated. In 2018, in key provincial and municipal public hospital terminals, the above-mentioned products in addition to the saline acid Changchun Ruibin injection, the rest of the products sales are more than 100 million yuan, injection sales of 1.61 billion yuan, injection sales of pentacycline 700 million yuan, injection sales of gisitamine 660 million yuan, lysine glucose injection 540 million yuan. (Minenet)